Investigational Drug Information for RPC1063
✉ Email this page to a colleague
What is the drug development status for RPC1063?
RPC1063 is an investigational drug.
There have been 13 clinical trials for RPC1063.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 3rd 2013.
The most common disease conditions in clinical trials are Sclerosis, Multiple Sclerosis, and Ulcer. The leading clinical trial sponsors are Celgene, Bristol-Myers Squibb, and Celgene Corporation.
There are thirty US patents protecting this investigational drug and four hundred and forty-six international patents.
Summary for RPC1063
| US Patents | 30 |
| International Patents | 446 |
| US Patent Applications | 249 |
| WIPO Patent Applications | 218 |
| Japanese Patent Applications | 66 |
| Clinical Trial Progress | Phase 3 (2013-12-03) |
| Vendors | 48 |
Recent Clinical Trials for RPC1063
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy | Bristol-Myers Squibb | Phase 2/Phase 3 |
| A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis | Bristol-Myers Squibb | Phase 2/Phase 3 |
| A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects | Celgene | Phase 1 |
Clinical Trial Summary for RPC1063
Top disease conditions for RPC1063
Top clinical trial sponsors for RPC1063
US Patents for RPC1063
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| RPC1063 | ⤷ Try a Trial | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (Foster City, CA) | ⤷ Try a Trial |
| RPC1063 | ⤷ Try a Trial | Kinase inhibitors | Respivert Limited (High Wycombe, Buckinghamshire, GB) Topivert Pharma Limited (London, GB) | ⤷ Try a Trial |
| RPC1063 | ⤷ Try a Trial | Kinase inhibitors | Respivert Limited (N/A) Topivert Pharma Limited (London, GB) | ⤷ Try a Trial |
| RPC1063 | ⤷ Try a Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Try a Trial |
| RPC1063 | ⤷ Try a Trial | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | CELGENE INTERNATIONAL II S RL (Couvet, CH) | ⤷ Try a Trial |
| RPC1063 | ⤷ Try a Trial | Proteins for the treatment of epithelial barrier function disorders | Second Genome, Inc. (South San Francisco, CA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for RPC1063
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| RPC1063 | Argentina | AR108926 | 2036-06-30 | ⤷ Try a Trial |
| RPC1063 | Australia | AU2017289158 | 2036-06-30 | ⤷ Try a Trial |
| RPC1063 | Canada | CA3029457 | 2036-06-30 | ⤷ Try a Trial |
| RPC1063 | European Patent Office | EP3478674 | 2036-06-30 | ⤷ Try a Trial |
| RPC1063 | Spain | ES2800339 | 2036-06-30 | ⤷ Try a Trial |
| RPC1063 | Japan | JP2019519580 | 2036-06-30 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
